Details

Autor(en) / Beteiligte

• Kanbayashi, Yuko
• Ishizuka, Yuichi
• Shimizu, Mayumi
• Sawa, Shohei
• Yabe, Katsushige
• Uchida, Mayako

Titel

Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis

Ist Teil von

• Supportive care in cancer, 2022-07, Vol.30 (7), p.5831-5836

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose To identify risk factors for opioid-induced constipation (OIC). Methods This study retrospectively analyzed 175 advanced cancer patients who were receiving pain treatment with opioids and were newly prescribed laxatives for OIC at Seirei Hamamatsu General Hospital between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from clinical records. The effect of newly prescribed laxatives for OIC was evaluated as “effective” in cases where the number of spontaneous bowel movements increased at least once in the first 3 days. The OIC was defined based on Rome IV diagnostic criteria. Multivariate logistic regression analysis was performed to identify risk factors for OIC. Optimal cutoff thresholds were determined using receiver operating characteristic analysis. Values of P  < 0.05 (two-tailed) were considered significant. Results Significant factors identified included body mass index (BMI) (odds ratio [OR] = 0.141, 95% confidence interval [CI] = 0.027–0.733; P  = 0.020), chemotherapy with taxane within 1 month of evaluation of laxative effect (OR = 0.255, 95% CI = 0.068–0.958; P  = 0.043), use of naldemedine (OR = 2.791, 95% CI = 1.220–6.385; P  = 0.015), and addition or switching due to insufficient prior laxatives (OR = 0.339, 95% CI = 0.143–0.800; P  = 0.014). Conclusion High BMI, chemotherapy including a taxane within 1 month of evaluation of laxative effect, no use of naldemedine, and addition or switching due to insufficient prior laxatives were identified as risk factors for OIC in advanced cancer patients with cancer pain.